TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31436452

Group type: EXPERIMENTAL
Intervention: Dichotic-listening task training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Auditory duration discrimination task (Control)
Number of subjects: 75
Study: 31334703

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day and EPA 1,800 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: rosuvastatin 2.5 mg/day
Number of subjects: 50
Study: 29100524

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ketamine with magnesium sulfate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25666295

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 152
Study: 24032427

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 223

Group type: COMPARATOR
Intervention: No-Adrenaline
Number of subjects: 223
Study: 21857944

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day) for three days prior to oGTT testing
Number of subjects: 15
Study: 19039620

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration (0.4 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Head-up tilt test (HUT)
Number of subjects: 18
Study: 17215529

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interferon alfa (9 MU subcutaneously three times weekly)
Number of subjects: 750
Study: 14756383

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Itraconazole (200 mg oral)
Number of subjects: 12
Study: 11466256

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: All three drugs (Timolol, Betaxolol, Carteolol)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Visual fields analysis
Number of subjects: 153
Study: 9568218

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7921931

Group type: EXPERIMENTAL
Intervention: Continuous intermuscular wound infusion with 0.25% bupivacaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 3360173

Group type: EXPERIMENTAL
Intervention: 2.5 mg norethisterone (NE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg norethisterone (NE)
Number of subjects: 24
Study: 31587622

Group type: EXPERIMENTAL
Intervention: RE+HRE
Number of subjects: 40

Group type: COMPARATOR
Intervention: RE
Number of subjects: 40
Study: 29782075

Group type: COMPARATOR
Intervention: Standard Care group
Number of subjects: 912
Study: 29114516

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dynamic strengthening
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 44
Study: 26330412

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 15179

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 15179

Group type: EXPERIMENTAL
Intervention: Both treatments (Ezetimibe/simvastatin and Simvastatin)
Number of subjects: 15179
Study: 23985232

Group type: EXPERIMENTAL
Intervention: Knowing ≥ 5 quitters
Number of subjects: 430

Group type: COMPARATOR
Intervention: Knowing no quitters
Number of subjects: 430
Study: 21205113

Group type: EXPERIMENTAL
Intervention: IV glucose (0.3 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV fructose (0.3 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 9
Study: 18496342

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16278102

Group type: EXPERIMENTAL
Intervention: Self-care skills training (Expert Patients Programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 14592361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 10932370

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 5778

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 5778
Study: 8824693

Group type: COMPARATOR
Intervention: 12 mg spirapril (first dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 12 mg spirapril (chronic treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 3 mg spirapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: 12 mg spirapril
Number of subjects: 24
Study: 1358158

Group type: EXPERIMENTAL
Intervention: Butylamino-phenoxy-propanol-acetate (BPPA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3918993

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg/day, increased to 100-300 mg/day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Imipramine (50 mg/day, increased to 100-300 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 30964824

Group type: EXPERIMENTAL
Intervention: Accurately measured office blood pressure (OBP)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP)
Number of subjects: 919
Study: 29357293

Group type: EXPERIMENTAL
Intervention: Active mandibular advancement splint (MAS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham mandibular advancement splint (MAS)
Number of subjects: 18
Study: 27146667

Group type: EXPERIMENTAL
Intervention: SpeedCourt intervention (28 athletes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular stabilization program (22 athletes)
Number of subjects: 50
Study: 24748161

Group type: EXPERIMENTAL
Intervention: Surgery at hospitals with at least 500 beds
Number of subjects: 35946

Group type: EXPERIMENTAL
Intervention: Surgery (general)
Number of subjects: 35946

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 35946

Group type: EXPERIMENTAL
Intervention: Census-tract poverty rate
Number of subjects: 35946

Group type: EXPERIMENTAL
Intervention: Diagnosis of colon cancer (versus rectal cancer)
Number of subjects: 35946
Study: 22704284

Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 549
Study: 20949133

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 30

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 30
Study: 17065257

Group type: EXPERIMENTAL
Intervention: Bivalent meningococcal outer membrane vesicle vaccine (B:4:P1.19,15 and B:4:P1.7‐2,4)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule)
Number of subjects: 321
Study: 16263208

Group type: EXPERIMENTAL
Intervention: Dietary supplement (soy, isoflavones, lycopene, silymarin, antioxidants)
Number of subjects: 49
Study: 11874927

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Buffered Regular Insulin (BR)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Number of subjects: 146
Study: 10450255

Group type: EXPERIMENTAL
Intervention: Clozapine add-on treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (no clozapine)
Number of subjects: 38
Study: 7851193

Group type: EXPERIMENTAL
Intervention: Controlled-release mesalamine at 4 g/day for 12 months
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 2186351

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZ) and Ampicillin (AMP)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Amikacin (AM) and Ampicillin (AMP)
Number of subjects: 147
Study: 395525

Group type: EXPERIMENTAL
Intervention: 200 mg danazol daily for 100 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30577050

Group type: EXPERIMENTAL
Intervention: Bipolar sealer
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 101
Study: 30664457

Group type: EXPERIMENTAL
Intervention: Immediate access to Music eScape mobile app
Number of subjects: 169

Group type: COMPARATOR
Intervention: Delayed access to Music eScape mobile app
Number of subjects: 169
Study: 29107562

Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy (50 mg once a day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Delayed switch to Dolutegravir monotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Combination ART
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy
Number of subjects: 104
Study: 24858231

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) dezocine (Group D)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 108
Study: 23242974

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 64
Study: 22156542

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 33 μg/kg/day
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 67 μg/kg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Untreated control (UC) group at 33 μg/kg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Untreated control (UC) group at 67 μg/kg/day
Number of subjects: 96
Study: 19188504

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IPC)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control (uninflated cuff)
Number of subjects: 242
Study: 17827633

Group type: COMPARATOR
Intervention: Initial antithrombin (AT) levels
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Initial antithrombin (AT) levels at 15 mg/dL
Number of subjects: 54
Study: 15155311

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 106

Group type: COMPARATOR
Intervention: remifentanil
Number of subjects: 106
Study: 11354520

Group type: EXPERIMENTAL
Intervention: Competitive male cyclists (CG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary men (SG)
Number of subjects: 12
Study: 9891195

Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 394

Group type: COMPARATOR
Intervention: Other laxatives (mainly lactulose)
Number of subjects: 394
Study: 8022533

Group type: EXPERIMENTAL
Intervention: 100 micrograms triiodothyronine (T3) administered orally for 3 consecutive days
Number of subjects: 14
Study: 2684495

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO2R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional continuous positive pressure ventilation (CPPV)
Number of subjects: 0
Study: 1096901

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indometacin 100 mg daily
Number of subjects: 50
Study: 30273568

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 835

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 835
Study: 28203023

Group type: EXPERIMENTAL
Intervention: Endovascular reconstruction of superficial femoral artery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-reconstruction group (control)
Number of subjects: 36
Study: 23728804

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 20
Study: 23211335

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 72

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 72
Study: 21672312

Group type: EXPERIMENTAL
Intervention: Modification of TEE probe placement protocol (Group II): Probe inserted after anaesthetic induction, removed after heart examination, reinserted before weaning from cardiopulmonary bypass, and removed immediately after examination.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard TEE probe placement protocol (Group I): Probe inserted after anaesthetic induction and remained in place until completion of surgery.
Number of subjects: 200
Study: 19456248

Group type: EXPERIMENTAL
Intervention: AndGynFM ratio
Number of subjects: 122
Study: 17875005

Group type: EXPERIMENTAL
Intervention: 270 microg/week of pegylated IFN‐alpha2a for 4 weeks followed by 180 microg/week for 8 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: 180 microg/week for 12 weeks
Number of subjects: 116
Study: 12482562

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg once daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10686469

Group type: EXPERIMENTAL
Intervention: Seropositive subjects
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Seronegative recruits
Number of subjects: 1156
Study: 9175386

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard antidepressants
Number of subjects: 11
Study: 8380266

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg, 4 times daily for 8 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 3298387

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of bovine superoxide dismutase (SOD) at a dosage of 0.25 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study: 29193662

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60
Study: 28031759

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) at frequency of 35Hz combined with pulmonary rehabilitation (NMES+RP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation only (RP)
Number of subjects: 30
Study: 24957950

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (Intanza)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular vaccination (Vaxigrip)
Number of subjects: 100
Study: 23301465

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (acupuncture, Chinese herbal medicine, rehabilitation)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 240

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Chinese herbal medicine
Number of subjects: 240
Study: 20540666

Group type: EXPERIMENTAL
Intervention: 4 g daily EPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 g daily DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (control group)
Number of subjects: 0
Study: 18560581

Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 1319
Study: 15984577

Group type: EXPERIMENTAL
Intervention: Vital exhaustion (VE) present
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vital exhaustion (VE)
Number of subjects: 0
Study: 12616128

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.1 mg/kg twice a day (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 14
Study: 10854812

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg orally, qds for 10 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg orally, bd for 10 days
Number of subjects: 10
Study: 9049766

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression garments
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 50
Study: 1846793

Group type: EXPERIMENTAL
Intervention: Intensity measurement using modified Borg scale during exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Distress measurement using modified Borg scale during exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation analysis between 'intensity' and minute ventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Slope comparison of 'intensity' and 'distress' against minute ventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation analysis between 'intensity' and 'distress' within individuals
Number of subjects: 10
Study: 6178250

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulphated polysaccharide (PZ 68)
Number of subjects: 100
Study: 30944029

Group type: EXPERIMENTAL
Intervention: CytoSorb® HA during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30
Study: 30117300

Group type: EXPERIMENTAL
Intervention: Moxidectin (4 mg, 8 mg, 16 mg, 24 mg, or 36 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27258494

Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAT) (>12 months)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Short-term dual antiplatelet therapy (DAT) (<12 months)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy for >12 months
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Clopidogrel therapy for <12 months
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Long-term DAT
Number of subjects: 1010
Study: 25532604

Group type: EXPERIMENTAL
Intervention: TVT Secur
Number of subjects: 74

Group type: COMPARATOR
Intervention: TVT
Number of subjects: 74
Study: 22034545

Group type: EXPERIMENTAL
Intervention: Case-based e-learning
Number of subjects: 141

Group type: COMPARATOR
Intervention: Text-based learning
Number of subjects: 141
Study: 21134043

Group type: EXPERIMENTAL
Intervention: RT001 Botulinum Toxin Type A Topical Gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17646515

Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine 1 microg/kg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 83
Study: 15767827

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER) 20 mg every 12 hours
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 153
Study: 12852712

Group type: EXPERIMENTAL
Intervention: IV linezolid 600 mg every 12 hours for 7 to 21 days
Number of subjects: 623

Group type: COMPARATOR
Intervention: IV vancomycin 1 g every 12 hours for 7 to 21 days
Number of subjects: 623
Study: 10380587

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (alone or combined with interferon)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (patients older than 55 years)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (patients younger than 55 years)
Number of subjects: 141
Study: 8853535

Group type: EXPERIMENTAL
Intervention: Palliative thoracic radiotherapy (external beam radiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation and chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Five fractions of radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and low-dose radiation protocol
Number of subjects: 0
Study: 1745488

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide, dexamethasone, and lorazepam (MDL)
Number of subjects: 145

Group type: COMPARATOR
Intervention: High-dose alizapride, dexamethasone, and lorazepam (ADL)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: MDL
Number of subjects: 145

Group type: COMPARATOR
Intervention: ADL
Number of subjects: 145
Study: 6293334

Group type: EXPERIMENTAL
Intervention: i.v. ranitidine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 12
Study: 31492050

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 8
Study: 29237487

Group type: EXPERIMENTAL
Intervention: Graduated transition and organized support group intervention
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual practice of abrupt transfer
Number of subjects: 216
Study: 25119512

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) activated
Number of subjects: 14

Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) deactivated
Number of subjects: 14
Study: 25117929

Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 245
Study: 22298600

Group type: EXPERIMENTAL
Intervention: Energy drink (Red Bull Energy Drink, 80 mg caffeine, 1000 mg taurine in 8.3 oz serving)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Caffeine supplementation (compounded caffeine solution, 80 mg caffeine in 8 oz bottled water)
Number of subjects: 9
Study: 19187525

Group type: EXPERIMENTAL
Intervention: Field mosquitoes (human odour)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Laboratory mosquitoes (human odour)
Number of subjects: 2

Group type: COMPARATOR
Intervention: CO2 effect
Number of subjects: 2
Study: 18082528

Group type: EXPERIMENTAL
Intervention: 2-dimensional handheld ultrasound device
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Ultrasound volume scanner
Number of subjects: 146
Study: 10890582

Group type: EXPERIMENTAL
Intervention: Standardized normal meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High fat/high protein diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 12
Study: 8813254

Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Nodal observation
Number of subjects: 740
Study: 1318391

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B) ingestion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (P) ingestion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (C - no ingestion)
Number of subjects: 7
Study: 3909471

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg + codeine phosphate 30 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 129
Study: 29049268

Group type: EXPERIMENTAL
Intervention: Providence Pedi Cast-Sling (PPCS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard sling
Number of subjects: 100
Study: 29920745

Group type: EXPERIMENTAL
Intervention: Avatar-based education plus usual care
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study: 27255456

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of Tribulus terrestris (1000 mg/d)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98